| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 30/05/2024 | 22:03 | PR Newswire (US) | Viking Therapeutics to Participate at Upcoming Investor Conferences | NASDAQ:VKTX | Viking Therapeutics Inc |
| 22/05/2024 | 23:12 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:VKTX | Viking Therapeutics Inc |
| 22/05/2024 | 22:33 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:VKTX | Viking Therapeutics Inc |
| 24/04/2024 | 22:05 | PR Newswire (US) | Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:VKTX | Viking Therapeutics Inc |
| 24/04/2024 | 13:31 | IH Market News | U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading | NASDAQ:VKTX | Viking Therapeutics Inc |
| 17/04/2024 | 22:05 | PR Newswire (US) | Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 | NASDAQ:VKTX | Viking Therapeutics Inc |
| 26/03/2024 | 12:03 | PR Newswire (US) | Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 | NASDAQ:VKTX | Viking Therapeutics Inc |
| 05/03/2024 | 01:54 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VKTX | Viking Therapeutics Inc |
| 04/03/2024 | 22:52 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VKTX | Viking Therapeutics Inc |
| 04/03/2024 | 22:45 | PR Newswire (US) | Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares | NASDAQ:VKTX | Viking Therapeutics Inc |
| 01/03/2024 | 22:13 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:VKTX | Viking Therapeutics Inc |
| 29/02/2024 | 02:50 | PR Newswire (US) | Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock | NASDAQ:VKTX | Viking Therapeutics Inc |
| 27/02/2024 | 22:19 | PR Newswire (US) | Viking Therapeutics Announces Proposed Public Offering of Common Stock | NASDAQ:VKTX | Viking Therapeutics Inc |
| 27/02/2024 | 13:03 | PR Newswire (US) | Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity | NASDAQ:VKTX | Viking Therapeutics Inc |
| 09/02/2024 | 22:01 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:VKTX | Viking Therapeutics Inc |
| 07/02/2024 | 23:24 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:VKTX | Viking Therapeutics Inc |
| 07/02/2024 | 22:05 | PR Newswire (US) | Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update | NASDAQ:VKTX | Viking Therapeutics Inc |
| 31/01/2024 | 22:05 | PR Newswire (US) | Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024 | NASDAQ:VKTX | Viking Therapeutics Inc |
| 13/11/2023 | 22:02 | PR Newswire (US) | Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023 | NASDAQ:VKTX | Viking Therapeutics Inc |
| 25/10/2023 | 23:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:VKTX | Viking Therapeutics Inc |
| 25/10/2023 | 22:05 | PR Newswire (US) | Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update | NASDAQ:VKTX | Viking Therapeutics Inc |
| 23/10/2023 | 13:05 | PR Newswire (US) | Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity | NASDAQ:VKTX | Viking Therapeutics Inc |
| 18/10/2023 | 22:05 | PR Newswire (US) | Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023 | NASDAQ:VKTX | Viking Therapeutics Inc |
| 18/10/2023 | 15:06 | IH Market News | Keep An Eye Out: Pre-Market Movers And Analyst Recommendations | NASDAQ:VKTX | Viking Therapeutics Inc |
| 18/10/2023 | 15:03 | IH Market News | Wednesday’s Wall Street Highlights: ASML, Nvidia, United Airlines, Viking Therapeutics, P&G, and More | NASDAQ:VKTX | Viking Therapeutics Inc |
| 17/10/2023 | 22:05 | PR Newswire (US) | Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023 | NASDAQ:VKTX | Viking Therapeutics Inc |
| 10/10/2023 | 22:05 | PR Newswire (US) | Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023 | NASDAQ:VKTX | Viking Therapeutics Inc |
| 06/09/2023 | 13:03 | PR Newswire (US) | Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity | NASDAQ:VKTX | Viking Therapeutics Inc |
| 26/07/2023 | 23:26 | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers | NASDAQ:VKTX | Viking Therapeutics Inc |
| 26/07/2023 | 22:05 | PR Newswire (US) | Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update | NASDAQ:VKTX | Viking Therapeutics Inc |